UnitedHealth price target lowered to $570 from $600 at Argus

Argus lowered the firm’s price target on UnitedHealth to $570 from $600 and keeps a Buy rating on the shares. The analyst says that while the Centers for Medicare & Medicaid Services final Medicare rate increase for 2025 was a disappointment, UnitedHealth has levers to preserve or even improve profit margins in its Medicare Advantage business. The firm reduced estimates but continues to be “impressed” by the organic growth at OptumHealth, OptumInsight and OptumRx.